Autonomix

Autonomix

Growth Stage

Breakthrough Technology For The Nervous System

Breakthrough Technology For The Nervous System

Overview

Raised this Round: Raised: $6,200,610

Total Commitments ($USD)

Platform

Dealmaker Securities

Start Date

10/18/2023

Close Date

01/29/2024

Min. Goal
$750
Max. Goal
$21,203,750
Min. Investment

$750

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$5.00

Pre-Money Valuation

$70,000,000

Year Founded

2014

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

The Woodlands, Texas

Business Type

Growth

Autonomix, with a valuation of $70 million, is raising funds independently through Reg A+ crowdfunding. The company is developing a two-fold technology to detect malfunctioning neural signals and ablate nerves. Autonomix is opening up a world of possibilities in electrophysiology and working towards creating a simple procedure for pain management. The company is currently targeting pancreatic cancer pain and aims to target chronic pain, cardiovascular pain, and pulmonary diseases in the future. Dr. Robert Schwartz, Landy Roth, David Robins, and Dr. Robert Van Tassel founded Autonomix in 2014. The current crowdfunding campaign has a maximum target of $21.2 million. The campaign proceeds will be used for marketing, publishing, underwriting expenses, legal & accounting fees, and transfer agent.

Balance Sheet

Cash and Cash Equivalents

$864,618

Investment Securities

$0

Accounts and Notes Receivable

$0

Property, Plant and Equipment (PP&E)

$0

Property and Equipment

$0

Total Assets

$864,618

Accounts Payable & Accrued Liabilities

$220,590

Long Term Debt

$0

Total Liabilities

$220,590

Total Stockholders' Equity

$6,440,281

Total Liabilities and Equity

$864,618

Statement of Comprehensive Income Information

Total Revenues

$0

Costs & Expenses Applicable to Rev

$0

Depreciation and Amortization

$0

Net Income

$-1,990,477

Earnings Per Share - Basic

$-0.17

Earnings Per Share - Diluted

$-0.17

Auditor: FORVIS, LLP
Financials as of: 10/18/2023
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Autonomix on Self Managed 2023
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $70,000,000
Price per Share: $5.00

Follow company

Follow Autonomix on Self Managed 2023

Buy Autonomix's Deal Report

Warning: according to the close date for this deal, Autonomix may no longer be accepting investments.

Autonomix Deal Report

Get KingsCrowd’s comprehensive report on Autonomix including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Autonomix is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Autonomix deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge